Skip to main content
editor.ajphr@gmail.com
9409046853
e-ISSN: 2321-3647
American Journal of Pharmacy and Health Research

American Journal of Pharmacy and Health Research

📢 Latest Update: Call for Papers 2026 | Submit Your Research to an International Peer-Reviewed Open Access Pharmacy Journal

📢 Latest Update: Call for Papers 2026 | Submit Your Research to an International Peer-Reviewed Open Access Pharmacy Journal

Volume 14, Issue 11 - 2026 (November 2026 Issue 11)

Volume 14 Issue 11 Cover

Issue Details:

Volume 14 Issue 11
Published:Nov 2, 2026

Editorial: November 2026 Issue 11

Welcome to the 2026 issue of American Journal of Pharmacy and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr H J Patel
Editor in Chief
American Journal of Pharmacy and Health Research

Articles in This Issue

Showing 2 of 2 articles
Research PaperID: AJPHR11140001Pages 1-12Open AccessOpen Access

In Silico Evaluation of Gossypium Hirsutum Phytoconstituents against Gastric H+/K+-ATPASE

Dr. V.P.Rode, Mr. Aayush Pandit, Hoshal Hirwani, Dr. Nitu Madan, Jagruti Walde, Dr. Amit Maliye

Methods: Seventeen phytoconstituents of G. hirsutum were selected for molecular docking against the gastric H+/K+-ATPase structure obtained from the Protein Data Bank (PDB ID: 5YLU). Ligands and protein were prepared using appropriate molecular modelling tools, and docking was performed using AutoDock Vina through PyRx. Protein-ligand interactions were subsequently examined using BIOVIA Discovery Studio Visualizer. Physicochemical and drug-likeness characteristics were evaluated using SwissADME. Results: The docking study will identify phytoconstituents exhibiting favorable predicted binding affinities toward gastric H+/K+-ATPase. The compounds showing the most favorable docking scores and relevant interactions with the receptor will be considered priority candidates for further investigation. Drug-likeness analysis will provide additional information regarding their physicochemical properties and compliance with commonly used medicinal-chemistry filters. Conclusion: The proposed computational investigation provides a preliminary structure-based assessment of G. hirsutum phytoconstituents against gastric H+/K+-ATPase. Compounds demonstrating favorable docking profiles may serve as candidates for subsequent experimental evaluation. However, molecular docking predictions alone cannot establish antiulcer efficacy, pharmacological activity, bioavailability, or safety and therefore require validation through appropriate in vitro and in vivo studies.

gastric proton pumpmolecular dockingphytoconstituentsGossypium hirsutumAutoDock Vinadrug-likeness
115,617 views
34,840 downloads

Contributors:

 Dr. V.P.Rode
,
 Mr. Aayush Pandit
,
 Hoshal Hirwani
,
 Dr. Nitu Madan
,
 Jagruti Walde
,
 Dr. Amit Maliye
Research PaperID: AJPHR11140002Pages 13-24Open AccessOpen Access

ASSESSMENT OF INTRAVENOUS HIGH-RISK MEDICATION MANAGEMENT IN A TERTIARY CARE HOSPITAL

Rajat Garg, Hemant Bhardwaj, Anjum Qadir Lone, Dr Tarun Singh, Bimal K Agrawal

Iatrogenic harm induced from medication occur at a rate more than one fourth in general wards and more than three fourth in ICUs, it estimated that during a critical care stay 1.7 medication errors per patient could be potentially life-threatening especially from drug given intravenously. We Aimed to assess the intravenous high-risk medication management in tertiary care hospital, and analyze utilization of IV high-risk medication dilution, diluent and duration. Methods Prospective controlled study involving 250 participants evaluated the utilization patterns of intravenous high-risk medications in equal divided groups, with a focus on dilution practices, diluent selection, and duration of administration in a critical care unit over a period of six months. A researcher observed this study by reviewing all the Patient Infusion Charts, Critical Care Flow Sheet and Syringe pump/infusions. Baseline severity was assessed using APACHE II and qSOFA scores. Categorical variables were analyzed using the Chi-square test. Results A total of 250 participants were enrolled and equally allocated into two groups 125 intervention and 125 Control. Analyzing the baseline clinical severities parameters including APACHE II scores (p = 0.845) and qSofa (p = 0.589) were distinguished between groups. No statistically significant differences were observed in primary clinical outcomes such as mortality (p =0.447) or discharge status (p = 0.609). A researcher independent double-checking before medication administration was documented in 81 (64.8%) intervention patients compared to 79 (63.2%) control patients (p =0.895). Conclusion In conclusion, primary outcomes were statistically distinct between the study groups, pharmacist-led observation and independent double-checking protocols established structured standardization in IV drug dilution, diluent selection, and infusion rate monitoring. Further research using more sensitive methods to assess key variables will provide a clearer and more comprehensive understanding of the true impact of pharmacist-led care on clinical outcomes. Keywords: High-Risk Medications; Intensive Care Units; Infusions; Patient Safety

High-Risk MedicationsIntensive Care UnitsInfusionsPatient Safety
116,102 views
34,722 downloads

Contributors:

 Rajat Garg
,
 Hemant Bhardwaj
,
 Anjum Qadir Lone
,
 Dr Tarun Singh
,
 Bimal K Agrawal
Whatsapp